RVMD

News RevMed Drug Delays Painful Cancer Symptoms While Extending Life

2d ago

Insider trade Sale by Mancini Anthony (See Remarks)

4d ago

News Why Is Cancer Drug Developer Erasca Stock Trading Lower Monday?

14d ago

News Natural Gas Rallies 30%, Silver Jumps 13% To $116: What's Moving Markets Monday?

14d ago

News Tango (TNGX) Q2 Revenue Drops 52%

14d ago

News Microsoft To Rally Around 6%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

14d ago

News Stanley Druckenmiller's Duquesne initiates stake in AVGO, dumps GOOGL among Q1 moves

17d ago

News Cancer Centers Race To Access Revolution Medicines' Pancreatic Cancer Treatment: Report

17d ago

News Revolution Medicines outlines $1.7B-$1.8B in 2026 GAAP operating expenses while expanding RASolve 301 to 590 patients

26d ago

News Organon & Co is the best performing healthcare stock in April

29d ago

News Revolution Medicines wins FDA nod to provide early access to cancer therapy

31d ago

Insider trade Sale by Anthony Mancini (Chief Global Commercialization Officer)

33d ago

News Revolution Medicines rival Erasca falls after early-stage trial data for cancer therapy

35d ago

Insider trade Sale by Mark A Goldsmith (President and Chief Executive Officer)

45d ago

News Revolution Medicines Announces Closing of Concurrent Upsized Public Offerings with Aggregate Gross Proceeds of Approximately $2.2 Billion, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

45d ago

News Revolution Medicines prices $2B in concurrent stock, notes offerings

48d ago

News Revolution Medicines plans $1B combined equity and convertible note offerings

49d ago

News Revolution Medicines Rallies After Phase 3 Pancreatic Cancer Trial Doubles Survival Versus Chemo

50d ago

News Revolution Medicines surges on data for pancreatic cancer asset daraxonrasib

50d ago

SEC filing RVMD Reports $13.2M Median OS, 0.40 HR PFS, Phase 3 RASolute 302 Data

50d ago

News RevMed’s Cancer Drug Nearly Doubles Overall Survival in Pivotal Study

50d ago

News Merck's $6.7 Billion Terns Pharmaceuticals Acquisition May Face Rival Interest: Analyst

68d ago

Insider trade Sale by Mark A Goldsmith (President and Chief Executive Officer)

74d ago

Insider trade Sale by Stephen Michael Kelsey (President, Research and Development)

74d ago

Insider trade Sale by Lin Wei (Chief Medical Officer)

74d ago